Introduction {#s001}
============

A[ttention-deficit/hyperactivity disorder (ADHD)]{.smallcaps} is a chronic neurobehavioral disorder affecting an estimated 7% of the population aged 18 years and under worldwide, and approximately half of the youth diagnosed with ADHD continue to have symptoms in adulthood (Kolar et al. [@B20]; Thomas et al. [@B36]). Psychostimulant medications, such as methylphenidate (MPH) and amphetamines, are widely regarded as offering the most effective control of core ADHD symptomatology and are generally well tolerated (Marcus et al. [@B21]; Antshel et al. [@B3]; Coghill et al. [@B9]; Felt et al. [@B14]).

There are many available formulations of both stimulant classes, including immediate-release, short-duration, and extended-release medications (Chavez et al. [@B6]). For MPH formulations, the efficacy of any particular formulation is related to its pharmacokinetic (PK) profile, as a formulation\'s PK profile over the day predicts its duration of efficacy (Coghill et al. [@B9]). While some children with ADHD continue to use immediate-release stimulant formulations as their primary medication or to augment other ADHD medications, long-acting formulations are currently preferred and more commonly prescribed (McCracken et al. [@B24]; Swanson and Hechtman [@B34]). Immediate-release stimulant formulations offer a 3- to 6-hour duration of action compared with longer-acting stimulant formulations, which offer an 8- to 12-hour duration of action (Chavez et al. [@B6]). Long-acting extended-release formulations allow for once-daily dosing and obviate the need for interruptions during the day, thus reducing the stigma associated with redosing during school hours (Feldman and Belanger [@B13]).

Long-acting MPH formulations deliver active drug through different methods. Many extended-release formulations produce an initial bolus delivery of immediate-release MPH that produces peak plasma concentrations 1--4 hours postdose followed by a long, controlled delivery of MPH that maintains plasma concentrations in the afternoon, effectively controlling symptoms for 8--12 hours after the initial dose (Swanson et al. [@B35]; Wolraich and Doffing [@B41]). Available extended-release formulations for ADHD include tablets, capsules, oral liquid suspensions, and a transdermal patch that can be worn up to 9 hours per day (Chavez et al. [@B6]). Additional stimulant formulations are currently in the pipeline (Childress and Tran [@B8]). Some of the long-acting stimulant capsules can be opened and sprinkled on certain foods (e.g., applesauce): however, not all long-acting medications can be sprinkled on foods or dissolved, and chewing or crushing is never permitted for any solid extended-release formulation (Wigal et al. [@B38]; Adderall XR^®^ Shire US Inc., Wayne, PA; Ritalin LA^®^ Novartis Pharmaceuticals Co., East Hanover, NJ; Focalin XR^®^ Novartis Pharmaceuticals Co., East Hanover, NJ; Metadate CD^®^ UCB Inc., Smyrna, GA; Vyvanse^®^ Shire US, Inc., Wayne, PA). Importantly, if the formulation is altered, the full dose of the extended-release stimulant may not be reliably administered and bioavailability of the medication may change.

When patients find it difficult to swallow medications, the results of treatment are often compromised. One study conducted in adults (\>18 years of age) who had a variety of medical disorders and who were taking multiple medications each day found that patients frequently avoided taking their medications or altered their oral-dose formulation to help with pill-swallowing difficulties by crushing or opening (Marquis et al. [@B23]). This practice can result in dose dumping of extended-release formulations (i.e., early release of a large amount or even most of the medication). Tablets and capsules should not be crushed or chewed, as these alterations to the route of administration can lead to adverse events (AEs) (Pleak [@B29]; Paparella [@B27]). Chewing MPH formulations with modified-release profiles has been reported to increase side effects such as nausea, abdominal pain, and disrupted eating while decreasing efficacy, likely due to the high peak plasma concentrations of active drug achieved in a short duration of time (Pleak [@B29]).

Difficulty in swallowing, or not wanting to swallow, solid oral dosage forms can also result in compromised adherence, leading to missed doses or discontinuation of drug therapy (Wigal et al. [@B38]). One study evaluating medication acceptance in children found that ∼70% of children 5--9 years old and 30% of children 10--14 years old could not easily swallow tablets and capsules similar in size to many of the available stimulant medications (Polaha et al. [@B30]). In some children, behavioral therapy was successful in addressing pill-swallowing aversions (Beck et al. [@B5]). The extent of pill aversion among patients with ADHD has not yet been systematically studied, and the potential impact of formulation on adherence in treating youth with ADHD is not yet known. However, delivering medication through formulations that are acceptable to children and that suit their size, age, physiologic condition, and treatment requirements is a recommended strategy in pediatrics to improve therapeutic outcomes (Ivanovska et al. [@B18]).

The availability of pediatric formulations has increased over recent years, but the market is largely limited to a few therapeutic areas, including respiratory and central nervous system (CNS) medications, hormones, and anti-infectives, emphasizing the unmet need for alternative formulations suitable for children in other disease areas (Balakrishnan et al. [@B4]; Ivanovska et al. [@B18]).

A new orally disintegrating tablet (ODT) formulation of MPH, which provides a PK profile consistent with once-daily dosing, has been developed by Neos Therapeutics, Inc. (NT0102 \[MPH XR-ODT\]; Childress et al. [@B7]). Orally disintegrating tablets that dissolve or disintegrate in the mouth without water traditionally have had immediate-release PK profiles (Saharan and Singh [@B33]); however, this formulation is the first extended-release MPH ODT. The XR-ODT formulation is made possible through ion-exchange resin technology. When the MPH salt is dissolved in the presence of the exchange resin, the positively charged mobile ion of the exchange resin (Na^+^) is replaced by the positively charged MPH molecule, resulting in stable MPH microparticles. MPH microparticles are either coated (extended-release) or uncoated (immediate-release) and compressed into ODTs. The coating controls the timing of drug release, enabling a modified release profile as the ODT formulation contains ∼30% immediate-release MPH and ∼70% extended-release MPH. The ODT disintegrates in the mouth without water and the disintegrated portions of the ODT are swallowed together with saliva.

The primary objective of this phase 1 study was to determine the PK profile of MPH XR-ODT in children and adolescents (6--17 years old) with ADHD.

Methods {#s002}
=======

This single-dose, open-label, single-period, single-treatment PK study was conducted at the Atlanta Center for Medical Research in accordance with the clinical research guidelines established by the basic principles defined in the United States Investigational New Drug regulations (21 Code of Federal Regulations Parts 50, 56, and 312), the principles enunciated in the International Conference on Harmonisation Guidelines for Good Clinical Practice, and the most recent guidelines of the Declaration of Helsinki (ICH [@B17]; World Medical Association [@B40]); it was approved by the IntegReview Ethical Review Board. Each participant and parent/legal guardian was provided with oral and written information describing the nature and duration of the study, in English. The participant must have had a parent or legal guardian who gave written informed consent for the child to participate in the study. The parent or guardian must have been able to read, speak, and understand English and be mentally and physically competent to provide written informed consent for their child. Signed assent was obtained from all children aged 6 years or older, or as per local or site requirements. Written informed consent/assent from both the parent/caregiver and children ≥6 years of age was obtained before performing any screening visit study-specific evaluations.

Participant demographics {#s003}
------------------------

Participants in this study were male and female, aged 6--17 years, and were stratified into four age groups: 6--7, 8--9, 10--12, and 13--17 years. Before study initiation, all participants were screened within 3 weeks before administration of study drug. All participants were required to have a primary diagnosis of ADHD (any subtype) based on *Diagnostic and Statistical Manual of Mental Disorders*, 4th Ed., Text Revision (DSM-IV-TR) criteria, as established by the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children---Present and Lifetime version (K-SADS-PL) (Kaufman et al. [@B19]; American Psychiatric Association [@B2]). Investigators also screened for comorbid psychiatric disorders; the Pediatric Baseline Version of the Columbia Suicide Severity Rating Scale (C-SSRS) was used to screen for suicidal ideation and behavior (Posner et al. [@B31]).

Inclusion/exclusion criteria {#s004}
----------------------------

Study participants were required to have had a favorable response to treatment with a stable dose of 40--60 mg of MPH hydrochloride (Metadate CD^®^) or a comparable dose(s) of an extended-release or immediate-release formulation of MPH hydrochloride (based on investigator determination) for at least 1 month and to have been under treatment for ADHD with an MPH-containing medication for a minimum of 3 consecutive months before study screening; this ensured that participants would be reasonably able to tolerate the medication dose used in this study. To confirm prior MPH use, a separate urine drug test obtained at screening tested for MPH and was expected to be positive. Pregnant females were excluded from the study and reliable contraception and urine pregnancy tests were required as appropriate. Exclusion criteria included a diagnosis or history of a tic disorder or Tourette\'s syndrome, as well as any family history of Tourette\'s syndrome; long QT syndrome or any clinically significant electrocardiogram (ECG) abnormality; history of suicidal ideation or behavior; other clinically significant psychiatric illnesses or substance abuse disorders; and clinically significant medical conditions, particularly cardiovascular disorders or any disorder or concomitant medications that could potentially alter the absorption, distribution, metabolism, or excretion of the study drug.

Medication {#s005}
----------

The study drug was an extended-release ODT formulation of MPH, provided as 30-mg tablets, for a total single-study dose of 60 mg (2 × 30 mg ODT) comprising both *d*-MPH and *l*-MPH enantiomers in a racemic mixture. A 60-mg dose was selected for this study because 60 mg is the maximum labeled dose for the reference formulation. Participants discontinued their current ADHD treatment regimen at least 4 days before dosing with MPH XR-ODT. Urine screening was performed to confirm that participants had been washed out from their usual MPH medication and were not using other ADHD medications or drugs of abuse. Gas chromatography/mass spectrometry was used to confirm the presence of the suspect analyte.

Procedures {#s006}
----------

Participants were admitted to the research facility the evening before dosing, fasted for at least 10 hours overnight, and then received a single dose of the study medication. MPH XR-ODTs were administered without water (other than a small mouth rinse to wet the mouth, which the participants spat out before study drug administration) and allowed to disintegrate in the mouth. The participants were permitted to move the study drug around in their mouth as needed while it disintegrated but were instructed not to chew or swallow the ODT intact. A mouth check was performed immediately after the dose was administered, to ensure that the disintegrated portion of the ODT had been swallowed. No food was permitted until 4 hours after dosing.

Eight blood samples for PK analysis were drawn during the treatment period; 3 mL blood samples were obtained before dosing and at selected times through 24 hours postdose: time 0 (predose) and at 0.75, 2, 3.5, 5.5, 8, 12, and 24 hours postdose. All PK samples, except the 24-hour blood draw, were collected while participants were inpatients. Plasma samples were analyzed for *d*-MPH and *l*-MPH using a validated liquid chromatography--mass spectrometry--mass spectrometry assay; concentration--time data for total MPH (*d-* + *l-*isomers summed) were used in the PK analysis. PK parameters for MPH were calculated for *d-*methylphenidate and *l-*methylphenidate separately as exploratory analyses.

Plasma samples were analyzed for *d*-MPH and *l*-MPH by Worldwide Clinical Trials; concentrations were reported in ng/mL to three significant figures and concentrations below limit of quantification (BLQ) were set to zero (0.00 ng/mL) in the data summarization. The analytical method was validated for a range of 0.250--50.0 ng/mL for *d*-MPH and 0.0100--2.00 ng/mL for *l*-MPH, based on 0.100 mL of K2-EDTA plasma. Quality control (QC) samples for *d*-MPH ranged from 0.750 to 40.0 ng/mL; the precision and accuracy for *d*-MPH analysis were 7.0% coefficient of variation (CV) and +6.5%, respectively. QC samples for *l*-MPH ranged from 0.0300 to 10.0 ng/mL; the precision and accuracy for *l*-MPH analysis were 8.2% CV and +7.7%, respectively. Study data were collected using Analyst^®^ (Version 1.4.2 or 1.6.1; Applied Biosystems/MDS Sciex) and Watson Laboratory Information Management System™ (LIMS, Version 7.2.0.03; Thermo Fisher Scientific) software. The concentration--time data were transferred from Watson LIMS directly to Phoenix WinNonlin (Version 6.3; Pharsight Corporation) using the Custom Query Builder option for analysis. PK calculations were performed by noncompartmental methods in WinNonlin.

In the PK analysis, BLQ concentrations were treated as zero from time-zero up to the time at which the first quantifiable concentration was observed; embedded and/or terminal concentrations BLQ were treated as "missing." Full precision concentration data (not rounded to three significant figures) and actual sample times were used for all PK and statistical analyses. The data from this study demonstrated that the *l*-isomer represents a negligible fraction of the plasma concentration in contrast to the more pharmacologically active *d*-isomer, which is consistent with the results from previous studies of oral MPH (Healand and Pierce [@B16]). The following plasma PK parameters were determined: maximum concentration (C~max~), time to maximum concentration (T~max~), elimination half-life (T~½~), area under the curve from time 0 hours to infinity (AUC~inf~), oral clearance (CL/F), and volume of distribution in the terminal phase (Vz/F); weight-normalized values of CL/F and Vz/F were also reported, as CL/F/kg and Vz/F/kg, respectively. PK parameters were summarized using descriptive statistics, and the geometric means and 95% confidence intervals (CIs) were calculated for weight-normalized CL/F and Vz/F in each age group to determine if the 95% CIs were within the target range of 60%--140%.

Safety data, including AEs (reported or observed), physical examinations, 12-lead ECGs, body weight, vital signs, clinical laboratory tests, and urine pregnancy tests, were collected. Urine was tested for the presence of alcohol, amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, propoxyphene, and tetrahydrocannabinol/marijuana at visit 1 (screening) and visit 2 (check-in for the study period). If urine drug screen results were positive, the corresponding gas chromatography/mass spectrometry confirmatory test was performed to confirm the suspect analyte. A separate urine drug screen was performed to assess for the presence of MPH at screening.

Results {#s007}
=======

Participants {#s008}
------------

A total of 33 participants enrolled in the study, with 1 participant discontinuing before receiving any study drug. Participants ranged in age from 6 to 17 years, with a greater percentage being male (75%) and black or African American (62.5%). Detailed demographic information and baseline characteristics of study participants are shown in [Table 1](#T1){ref-type="table"}.

###### 

[Participant Demographics and Baseline Characteristics]{.smallcaps}

  *Parameter*                                      *Study population*
  ------------------------------------------------ ----------------------
  Sex, *n* (%)                                     
   Total, male/female (*N* = 32)                   24 (75.0) / 8 (25.0)
   Age group 6--7 years, male/female (*n* = 8)     5 (62.5) / 3 (37.5)
   Age group 8--9 years, male/female (*n* = 8)     6 (75.0) / 2 (25.0)
   Age group 10--12 years, male/female (*n* = 8)   6 (75.0) / 2 (25.0)
   Age group 13--17 years, male/female (*n* = 8)   7 (87.5) / 1 (12.5)
  Race, *n* (%), (*N* = 32)                        
   White                                           11 (34.4)
   Black or African American                       20 (62.5)
   White and Black or African American             1 (3.1)
  Age, years, (*N* = 32)                           
   Mean ± SD                                       10.4 ± 3.7
   Range                                           6.0--17.0
  BMI, kg/m^2^, (*N* = 32)                         
   Mean ± SD                                       18.0 ± 2.8
  Weight, kg, mean ± SD                            
   Age group 6--7 years, (*n* = 8)                 25.9 ± 4.7
   Age group 8--9 years, (*n* = 8)                 31.5 ± 5.6
   Age group 10--12 years, (*n* = 8)               38.1 ± 6.6
   Age group 13--17 years, (*n* = 8)               63.0 ± 9.2

BMI, body mass index; *n*, number of participants; *N*, all participants; SD, standard deviation.

PK assessments {#s009}
--------------

The primary prespecified analysis of this study was to present the mean (± standard deviation \[SD\]) plasma *d+l* MPH concentration--time data by age group as shown in [Figure 1](#f1){ref-type="fig"}. Additionally, the mean (±SD) MPH concentration--time data are presented for all participants in [Figure 2](#f2){ref-type="fig"}. For all 32 participants, quantifiable plasma concentrations of MPH were observed at the first postdose PK time point (0.75 hours) and throughout the 24-hour sampling interval. As shown in [Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}, plasma concentration--time profiles of MPH exhibited a broad peak after administration of MPH XR-ODT through ∼8 hours, indicating extended release from the formulation, followed by an apparent first-order elimination phase.

![Mean total methylphenidate plasma concentration--time profiles for MPH XR-ODT under fasted conditions in children and adolescents by age. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.](fig-1){#f1}

![Mean total methylphenidate plasma concentration--time profiles for MPH XR-ODT under fasted conditions in children and adolescents. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.](fig-2){#f2}

The PK parameters for MPH are presented both by age group and for all participants in [Table 2](#T2){ref-type="table"}. MPH XR-ODT 60 mg displayed a PK profile similar to that of other long-acting MPH formulations, which achieve peak plasma concentration within several hours of dosing, followed by a slow descending MPH plasma concentration (Swanson et al. [@B35]). After a fixed 60-mg dose of MPH XR-ODT, the mean (SD) C~max~ was 30.1 (10.6) ng/mL for all participants (*n* = 32), occurring at mean (SD) T~max~ of 4.81 (1.48) hours. Mean (SD) overall systemic exposure to MPH, as measured by AUC~inf~, was 299 (104) ng·hour/mL (*n* = 30). Notable differences were observed in PK parameters across age groups with the 6- to 7-year age group exhibiting higher maximum plasma concentrations compared with the older age groups. The mean (SD) C~max~ ranged from 20.6 (5.97) ng/mL for the 13- to 17-year age group to 38.1 (7.88) ng/mL for the 6- to 7-year age group, occurring at median T~max~ between 3.5 and 5.5 hours. Likewise, overall systemic exposure to MPH, as measured by AUC~inf~, decreased with age; mean (SD) AUC~inf~ ranged from 190 (63) ng·hour/mL for the 13- to 17-year age group to 378 (104) ng·hour/mL for the 6- to 7-year age group. This decrease in MPH exposure with age reflects the established increase in MPH clearance with age seen in another MPH formulation (Concerta^®^ Janssen Pharmaceuticals, Inc., Titusville, NJ); mean (SD) CL/F ranged from 169 (45) L/hour for the 6- to 7-year age group to 343 (99) L/hour for the 13- to 17-year age group. However, appreciable differences in CL/F were not observed after these values were adjusted for the patients\' weight; the geometric mean CL/F/kg ranged from 5.35 to 6.44 L/(hour·kg). As shown in [Table 3](#T3){ref-type="table"}, the 95% CIs for the geometric mean CL/F/kg and Vz/F/kg fell within the target range of 60%--140% for each age group.

###### 

[Total Methylphenidate Pharmacokinetic Parameters of MPH XR-ODT]{.smallcaps}

  *Parameter*                        *6--7 years old (*n* = 8)*   *8--9 years old (*n* = 8)*                    *10--12 years old (*n* = 8)*   *13--17 years old (*n* = 8)*                  *Total (*N* = 32)*
  ---------------------------------- ---------------------------- --------------------------------------------- ------------------------------ --------------------------------------------- ---------------------------------------------
  T~max~ (hours), median (range)     3.5 (3.5--5.5)               5.5 (3.5--8.0)                                4.5 (2.0--8.0)                 5.5 (3.5--8.0)                                5.5 (2.0--8.0)
  Mean ± SD                          4.25 ± 1.04                  5.06 ± 1.55                                   4.62 ± 1.87                    5.31 ± 1.41                                   4.81 ± 1.48
  C~max~ (ng/mL), mean ± SD          38.1 ± 7.88                  30.7 ± 7.49                                   30.7 ± 12.9                    20.6 ± 5.97                                   30.1 ± 10.6
  AUC~inf~ (ng·hour/mL), mean ± SD   378 ± 104                    336 ± 37^[a](#tf2){ref-type="table-fn"}^      285 ± 95                       190 ± 63^[a](#tf2){ref-type="table-fn"}^      299 ± 104^[b](#tf3){ref-type="table-fn"}^
  T~½~ (hours), mean ± SD            5.03 ± 1.24                  4.34 ± 0.89^[a](#tf2){ref-type="table-fn"}^   3.87 ± 0.36                    3.92 ± 0.33^[a](#tf2){ref-type="table-fn"}^   4.30 ± 0.91^[b](#tf3){ref-type="table-fn"}^
  Vz/F (L), mean ± SD                1191 ± 269                   1140 ± 322^[a](#tf2){ref-type="table-fn"}^    1295 ± 439                     1901 ± 412^[a](#tf2){ref-type="table-fn"}^    1372 ± 460^[b](#tf3){ref-type="table-fn"}^
  CL/F (L/hour), mean ± SD           169 ± 45                     180 ± 20^[a](#tf2){ref-type="table-fn"}^      230 ± 69                       343 ± 99^[a](#tf2){ref-type="table-fn"}^      229 ± 92^[b](#tf3){ref-type="table-fn"}^

*n* = 7; AUC~inf~, T~½1/2~, Vz/F, and CL/F could not be estimated for one patient in this age group.

*N* = 30.

AUC~inf~, area under the curve from time 0 hours to infinity; CL/F, oral clearance; C~max~, maximum plasma concentration; MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets; *n*, number of participants; *N*, all participants; SD, standard deviation; T~½~, elimination half-life; T~max~, time to maximum plasma concentration; Vz/F, volume of distribution in the terminal phase.

###### 

[Statistical Analyses of Weight-Normalized Clearance and Volume of Distribution in the Terminal Phase of Total Methylphenidate by Age Group]{.smallcaps}

  *Parameter*                  n   *Geometric mean (95% CI)*   *Target CI interval range (60%--140%)*
  ---------------------------- --- --------------------------- ----------------------------------------
  Age group 1 (6--7 years)                                     
  Vz/F (L/kg)                  8   45.7 (36.2--57.7)           27.4--64.0
  CL/F (L/\[h·kg\])            8   6.44 (5.14--8.06)           3.86--9.02
  Age group 2 (8--9 years)                                     
  Vz/F (L/kg)                  7   34.5 (29.5--40.3)           20.7--48.3
  CL/F (L/\[h·kg\])            7   5.59 (4.98--6.28)           3.35--7.83
  Age group 3 (10--12 years)                                   
  Vz/F (L/kg)                  8   32.6 (25.0--42.5)           19.5--45.6
  CL/F (L/\[h·kg\])            8   5.87 (4.60--7.47)           3.52--8.22
  Age group 4 (13--17 years)                                   
  Vz/F (L/kg)                  7   30.1 (25.2--36.0)           18.1--42.2
  CL/F (L/\[h·kg\])            7   5.35 (4.24--6.73)           3.21--7.49

CI, confidence interval; CL/F/kg, weight-normalized oral clearance in the terminal phase; Vz/F/kg, weight-normalized volume of distribution in the terminal phase.

Reported adverse events {#s010}
-----------------------

Of the 33 participants enrolled in this study, 32 received the study medication. Consent was withdrawn by one participant who was discontinued early from the study before taking any study drug. There were a total of 34 AEs, with 22 participants (68.8%) experiencing an AE: 7 in age group 1 (6--7 years old), 7 in age group 2 (8--9 years old), 6 in age group 3 (10--12 years old), and 2 in age group 4 (13--17 years old). All 34 AEs were judged by the investigators to be mild and 33 were assessed as being related to the study drug. The most common AEs, occurring in \>5% of participants, are listed in [Table 4](#T4){ref-type="table"} and included increased heart rate, decreased appetite, nausea, and vomiting. The nature of the treatment-emergent AEs reported was consistent with the mechanism of action for the study medication. Clinical laboratory, ECG, and physical examination evaluations were completed with no clinically significant findings. There were no deaths, nonfatal serious AEs, or discontinuations due to AEs.

###### 

[Summary of Adverse Events (\>5%)]{.smallcaps}

  *Adverse event*                *Participants (*N* = 32),* n *(%)*
  ------------------------------ ------------------------------------
  Any adverse event (all mild)   22 (68.8)
  Increased heart rate           12 (37.5)
  Decreased appetite             11 (34.4)
  Nausea                         2 (6.3)
  Vomiting                       2 (6.3)

*n*, number of participants; *N*, all participants.

Discussion {#s011}
==========

The availability of alternative MPH dosage forms, including this novel XR-ODT formulation of MPH, may allow for increased flexibility for healthcare providers when choosing a formulation to align with individual patient needs (Coghill et al. [@B9]). The average T~max~ (4.25--5.31 hours) for total MPH was similar (although not identical) for all age groups and was consistent with previous reports of other long-acting MPH formulations (Ritalin LA^®^ Novartis Pharmaceuticals Co., East Hanover, NJ; Metadate CD^®^ UCB Inc., Smyrna, GA). Apparent differences in T~max~ across age groups reflect small differences in the plasma concentrations of MPH stemming from the extended-release characteristics of the formulation, as seen in [Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}. Quantifiable MPH concentrations were observed at the first PK time point (0.75 hours), and measurable concentrations of total MPH were observed throughout the 24-hour sampling interval for all participants, consistent with available once-daily MPH formulations (Wigal et al. [@B39]). The observed differences in exposure parameters were largely due to age-related weight disparities between the groups, except for the youngest age group (6--7 years), in which exposure was higher than in the other age groups, a previously observed phenomenon (Wigal et al. [@B39]). According to previously reported PK/pharmacodynamic (PD) modeling data comparing two different formulations of extended-release MPH, superior efficacy at any point in time was achieved for the MPH formulation with the highest plasma concentration (Swanson et al. [@B35]); therefore, due to the notable differences observed in C~max~ between age groups after a 60-mg dose of MPH XR-ODT, future efforts toward determining a weight-based PK/PD efficacy model are warranted.

Consistent with previously published studies of MPH PK, estimates of CL/F following oral MPH administration increased with age due to intrinsic body weight differences between younger children and adolescents (Wigal et al. [@B39]). However, when normalized by weight, CL/F values were comparable across age groups. Similarly, mean estimates of Vz/F of MPH increased with age, but the differences across the four age groups were less variable after weight normalization, with the exception of the youngest participants in the study (6--7 years old). The geometric means for CL/F/kg and Vz/F/kg of MPH and the respective 95% CIs were within the target range (60%--140%) for each of the four age groups.

One limitation of this study is that the sample of females is not large enough to enable comparison of PK characteristics of males versus females. Evidence suggests that female adults have lower plasma concentrations as compared with their male counterparts after receiving the same dosage of MPH (Markowitz et al. [@B22]). The extent to which the gender composition of the different age groups influenced the PK results in this study is not known. An additional limitation is that this was a single-dose study. A previous study of children and adolescents demonstrated that MPH accumulation did occur when participants were monitored for 7 days while taking fixed daily doses of long-acting MPH (osmotic-release oral system MPH) (Pierce et al. [@B28]). Yet the available evidence indicates that conventional extended-release tablet and capsule formulations of MPH do not accumulate (Ritalin LA^®^ Novartis Pharmaceuticals Co., East Hanover, NJ; Concerta^®^ Janssen Pharmaceuticals, Inc., Titusville, NJ); therefore, we do not expect that the PK profile of MPH XR-ODT would be altered over time.

Conclusions {#s012}
===========

The PK profile of MPH XR-ODT formulation is consistent with once-daily dosing similar to currently available oral formulations. This formulation demonstrated a similar safety and efficacy profile to that of the available extended-release MPH tablets and capsules in a phase 3 clinical efficacy and safety trial in children with ADHD (NCT01835548). This study demonstrated efficacy of MPH XR-ODT in a laboratory classroom setting from 1 hour through 12 hours postdose (Childress et al. [@B7]).

The other noteworthy finding of this study is the correlation of plasma concentration with age and weight. The latter finding suggests that more attention should be paid to the effects of weight on MPH dosing in subsequent clinical trials. If the clinical utility of weight-based dosing is confirmed, this would represent an important recommendation for clinical practice.

Clinical Significance {#s013}
=====================

This PK study of a novel MPH formulation, MPH XR-ODT, demonstrates a PK profile that is consistent with once-daily dosing, similar to available long-acting oral formulations of MPH. The new formulation disintegrates in the mouth without water and does not require chewing or swallowing an intact tablet. Orally disintegrating tablets have been suggested as effective alternatives to conventional tablet formulations for the treatment of another CNS disorder in adults (Dowson et al. [@B12]; Dowson and Charlesworth [@B11]). Orally disintegrating tablets also have been used successfully in children for treating various conditions, including asthma and nausea (Orapred ODT^®^ Shionogi Inc., Atlanta, GA; Zofran ODT^®^ GlaxoSmithKline., Research Triangle Park, NC). The extent to which different oral formulations affect treatment outcomes in ADHD remains unknown; however, MPH XR-ODTs may be an alternative to traditional extended-release stimulant formulations, as no measuring or opening capsules to sprinkle into food or liquid is required for ingestion.
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